Drugs / CMD-193
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00293215 | Feb 2006 → May 2007 | neoplasm | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT00257881 | Nov 2005 → Dec 2006 | neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00161642 | Nov 2004 → Jul 2007 | neoplasm | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMD-193 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00257881 ↗ |
| Modality | Monoclonal antibody | “CMD-193, a humanized monoclonal antibody linked to the toxin calicheamicin” NCT00293215 ↗ |
| Route | Intravenous | “CMD-193 administered intravenously (IV)” NCT00257881 ↗ |